MX390789B - Composición farmacéutica de dosis fija que comprende mometasona y azelastina. - Google Patents

Composición farmacéutica de dosis fija que comprende mometasona y azelastina.

Info

Publication number
MX390789B
MX390789B MX2019001701A MX2019001701A MX390789B MX 390789 B MX390789 B MX 390789B MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 390789 B MX390789 B MX 390789B
Authority
MX
Mexico
Prior art keywords
azelastine
mometasone
pharmaceutical composition
dose pharmaceutical
fixed
Prior art date
Application number
MX2019001701A
Other languages
English (en)
Other versions
MX2019001701A (es
Inventor
Piyush Agarwal
Sunil Chaudhari
Suresh Rajurkar
Ulhas R Dhuppad
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102013000830A external-priority patent/BR102013000830A2/pt
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2019001701A publication Critical patent/MX2019001701A/es
Publication of MX390789B publication Critical patent/MX390789B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica de dosis fija que comprende mometasona y azelastina. De forma particular, la presente invención proporciona una composición farmacéutica estable de dosis fija en la forma de un spray nasal que comprende mometasona o su sal y azelastina o su sal; y un proceso para preparar dicha composición, y su uso en el tratamiento de rinitis en un sujeto.
MX2019001701A 2012-12-06 2013-12-04 Composición farmacéutica de dosis fija que comprende mometasona y azelastina. MX390789B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3454MU2012 2012-12-06
BR102013000830A BR102013000830A2 (pt) 2013-01-11 2013-01-11 Composição farmacêutica para administração nasal, e, uso da mesma
PCT/IB2013/060638 WO2014087347A1 (en) 2012-12-06 2013-12-04 Fixed dose pharmaceutical composition comprising mometasone and azelastine

Publications (2)

Publication Number Publication Date
MX2019001701A MX2019001701A (es) 2019-08-14
MX390789B true MX390789B (es) 2025-03-21

Family

ID=50882873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001701A MX390789B (es) 2012-12-06 2013-12-04 Composición farmacéutica de dosis fija que comprende mometasona y azelastina.
MX2014003546A MX2014003546A (es) 2012-12-06 2013-12-04 Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014003546A MX2014003546A (es) 2012-12-06 2013-12-04 Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.

Country Status (7)

Country Link
EP (1) EP2928302A1 (es)
EA (1) EA037259B1 (es)
MX (2) MX390789B (es)
MY (1) MY196902A (es)
PH (1) PH12015501179A1 (es)
WO (1) WO2014087347A1 (es)
ZA (1) ZA201503799B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109288790A (zh) * 2017-07-25 2019-02-01 健乔信元医药生技股份有限公司 鼻用医药组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof

Also Published As

Publication number Publication date
MY196902A (en) 2023-05-09
EP2928302A1 (en) 2015-10-14
PH12015501179A1 (en) 2015-08-17
MX2019001701A (es) 2019-08-14
WO2014087347A1 (en) 2014-06-12
EA201491769A1 (ru) 2015-06-30
ZA201503799B (en) 2016-02-24
MX2014003546A (es) 2014-12-09
EA037259B1 (ru) 2021-03-01

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
PH12016500433B1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
TN2015000278A1 (en) Autotaxin inhibitors
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
JO3603B1 (ar) مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NZ702663A (en) Nuclear transport modulators and uses thereof
EA201690541A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
MX381932B (es) Composicion intranasal que comprende betahistina.
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX390789B (es) Composición farmacéutica de dosis fija que comprende mometasona y azelastina.
EP2905022A4 (en) PHARMACEUTICAL COMPOSITION BASED ON 1-ADAMANTYL-ETHYLOXY-3-MORPHOLINO-2-PROPANOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR TREATING CARDIOVASCULAR DISEASE